Adverse events (AEs) were documented using Common Terminology Criteria for Adverse Events, version 4. Alisertib dose levels/modifications are provided in eTable 1 in Supplement 2. Fulvestrant was not modified for AEs. If treatment with alisertib was paused due to toxic effects, then so was fulvestrant.
Within 14 days of registration, before each cycle, and at PD, patients underwent toxic effect assessments. Tumor assessments were performed after every 2 cycles.
Free full text: Click here